A new study published in JAMA reveals that estimating the treatment outcomes in meta-analyses depends significantly on the method of analysis strategy used and could lead to major alterations in the conclusions derived from the analysis.
Meta-analyses of randomized clinical trials (RCTs) are generally considered to provide among the best evidence of efficacy of medical interventions. They should be conducted as part of a systematic review, a scientifically rigorous approach that identifies, selects, and appraises all relevant studies. Which trials to combine in a metaanalysis remains a persistent dilemma. Meta-analysis of all trials may produce a precise but biased estimate, according to background information in the article.
Agnes Dechartres, M.D., Ph.D., of the Centre de Recherche Epidemiologie et Statistique, INSERM U1153, Paris, and colleagues compared treatment outcomes estimated by meta-analysis of all trials and several alternative strategies for analysis: single most precise trial (i.e., trial with the narrowest confidence interval), meta-analysis restricted to the 25 percent largest trials, limit meta-analysis (a meta-analysis model adjusted for small-study effect), and meta-analysis restricted to trials at low overall risk of bias. The researchers included 163 meta-analyses published between 2008 and 2010 in high-impact-factor journals and between 2011 and 2013 in the Cochrane Database of Systematic Reviews: 92 (705 RCTs) with subjective outcomes and 71 (535 RCTs) with objective outcomes.
"In this study, we compared meta-analysis of all trials with several 'bestevidence' alternative strategies and found that estimated treatment outcomes differed depending on the strategy used. We cannot say which strategy is the best because ... we cannot know with 100 percent certainty the truth in any research question. Nevertheless, our results raise important questions about meta-analyses and outline the need to rethink certain principles," the researchers write.
"We recommend that authors of meta-analyses systematically assess the robustness of their results by performing sensitivity analyses. We suggest the comparison of the meta-analysis result to the result for the single most precise trial or metaanalysis of the largest trials and careful interpretation of the meta-analysis result if they disagree."(doi:10.1001/jama.2014.8166;
Editor's Note: Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.
Editorial: Meta-analysis as Evidence - Building a Better Pyramid
Jesse A. Berlin, Sc.D., of Johnson & Johnson, Titusville, N.J., and Robert M. Golub, M.D., Deputy Editor, JAMA, write in an accompanying editorial that "findings such as those in the study by Dechartres et al reinforce concerns that journals and readers have about metaanalysis as a study design. Those findings deserve consideration not only in the planning of the studies but in the journal peer review and evaluation. They also reinforce the need for circumspection in study interpretation."
"Meta-analysis has the potential to be the best source of evidence to inform decision making. The underlying methods have become much more sophisticated in the last few decades, but achieving this potential will require continued advances in the underlying science, parallel to the advances that have occurred with other biomedical research design and statistics. Until that occurs, an informed reader must approach these studies, as with all other literature, as imperfect information that requires critical appraisal and assessment of applicability of the findings to individual patients. This is not easy, and it requires skill and intelligence. Whatever clinical evidence looks like, and wherever it is placed on a pyramid, there are no shortcuts to truth."(doi:10.1001/jama.2014.8167; )
Editor's Note: The authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest and none were reported.